Background-Conflicting evidence exists on sex-based outcomes after coronary stenting. Key Words: coronary disease Ⅲ bare metal stents Ⅲ drug-eluting stents Ⅲ proportional hazards models Ⅲ sex factors C oronary stenting has become a standard of care for the treatment of medically refractory coronary artery disease, with approximately one third of the estimated 596 000 annual percutaneous coronary interventions (PCIs) performed in women in the United States. 1 Although procedural success rates are similar by sex, 2-5 it remains unclear whether disparate in-hospital and long-term outcomes exist between the sexes. In addition, the long-term safety and effectiveness of drug-eluting stents (DES) relative to bare metal stents (BMS) in women are poorly understood. The pivotal randomized clinical trials of DES included Ͻ400 women (28%-32% of study populations), and sex-specific results were not provided. 6 -11 To date, observational studies of DES versus BMS in women have produced conflicting results, in part because of their small sample size and restricted ability to adjust for potentially important confounding factors. 12, 13 In recognition of this problem, the Food and Drug Administration has recently issued a draft guidance recommending the inclusion of women in representative numbers with analysis of sex-specific outcomes in trials of implantable medical devices. 14
C oronary stenting has become a standard of care for the treatment of medically refractory coronary artery disease, with approximately one third of the estimated 596 000 annual percutaneous coronary interventions (PCIs) performed in women in the United States. 1 Although procedural success rates are similar by sex, [2] [3] [4] [5] it remains unclear whether disparate in-hospital and long-term outcomes exist between the sexes. In addition, the long-term safety and effectiveness of drug-eluting stents (DES) relative to bare metal stents (BMS) in women are poorly understood. The pivotal randomized clinical trials of DES included Ͻ400 women (28%-32% of study populations), and sex-specific results were not provided. 6 -11 To date, observational studies of DES versus BMS in women have produced conflicting results, in part because of their small sample size and restricted ability to adjust for potentially important confounding factors. 12, 13 In recognition of this problem, the Food and Drug Administration has recently issued a draft guidance recommending the inclusion of women in representative numbers with analysis of sex-specific outcomes in trials of implantable medical devices. 14 
Clinical Perspective on p 2199
Using a very large contemporary cohort of 426 996 patients Ն65 years of age undergoing coronary stenting in US community practice, we sought to examine in-hospital and long-term outcomes by sex and to compare the long-term safety and effectiveness of DES and BMS in women and men.
Methods

NCDR and Centers for Medicare & Medicaid Services Data Sets and Linkage
The National Cardiovascular Data Registry (NCDR) CathPCI Registry collects detailed data on patient and hospital characteristics, clinical presentation, treatments, and in-hospital outcomes for PCI procedures from Ͼ1000 participating sites across the United States. Data are entered by sites into NCDR-certified software at participating institutions, which are subject to auditing. To promote and ensure the validity and veracity of submitted data, internal checks of the data are ensured by data quality reports on the submitted quarterly data, along with an external onsite auditing program. 15 To evaluate long-term outcomes, CathPCI Registry stent procedures between January 1, 2004 , and December 31, 2008, were linked to Medicare's 100% inpatient fee-for-service claims files using indirect identifiers (eg, index PCI procedure site, patient date of birth or age, admission, discharge date, and sex), as previously described. 16 Sites that did not match to Medicare records and patients whose index PCI procedure did not occur during a period of fee-for-service enrollment were excluded. Patients were also excluded if both BMS and DES were placed during the index event only. Longitudinal profiles were created with up to 62.7 months of patient follow-up (median, 20.4 months; 25th percentile, 9.1 months; 75th percentile, 32.8 months). The Duke University Medical Center Institutional Review Board granted a waiver of informed consent and authorization for this study.
Clinical End Points
Adverse in-hospital events were assessed with CathPCI Registry standard definitions 17 from version 3.04 of the data collection form and included the following primary end points: death, bleeding (requiring a blood transfusion, prolonged hospital stay, and/or drop in hemoglobin Ͼ3.0 g/dL), vascular complications, and periprocedural myocardial infarction (MI; definition based on ECG or biomarker elevation criteria either in the catheterization laboratory or during hospitalization). Biomarker threshold was defined as creatine kinase-MB (creatine kinase if creatine kinase-MB not present) Ͼ3 times the upper limit of normal after PCI. For coronary artery bypass grafting patients, biomarker elevation Ն5 times the upper limit of normal with the presence of Q waves or Ն10 times the upper limit of normal with or without Q waves within 24 hours of cardiac surgery was considered a periprocedural MI. ECG criteria included new ST elevations, left bundle-branch block, or new Q waves in 2 contiguous leads. 18 Bleeding complications included retroperitoneal bleeding, gastrointestinal bleeding, bleeding at the PCI entry site, and bleeding secondary to "other/unknown" causes. Vascular complications included access-site occlusion, peripheral embolization, dissection, pseudoaneurysm, and arteriovenous fistula. Additional end points included new incident congestive heart failure, incident cardiogenic shock, cerebrovascular accident, and renal failure.
Long-term events were ascertained from Medicare fee-for-service claims file data and Medicare denominator file data and were defined by primary procedural codes for hospitalization. 
Statistical Analysis
Sex-associated differences in baseline characteristics for the overall cohort were compared by use of 2 tests for categorical variables and the Wilcoxon rank-sum test for continuous variables. Univariate and multivariate logistic regression models containing Ͼ50 baseline clinical and angiographic factors were used to evaluate the association between sex and in-hospital outcomes (see the online-only Data Supplement). Unadjusted event rates were calculated at 900 days. Adjusted long-term outcomes were compared by sex with the use of Cox proportional hazards modeling. Survival estimates were based on weights that were functions of Kaplan-Meier censoring estimates, 19 whereas the cumulative incidence rates for nonfatal timeto-event outcomes were estimated to account for competing risks by use of the Gray methods. 20 Propensity matching was used to compare outcomes of DES and BMS in women and men. To create the propensity-matched cohort, the overall Medicare-linked CathPCI Registry cohort was first stratified by sex. Within each strata of sex, a propensity-matched cohort was created using Ͼ50 variables (see the online-only Data Supplement; similar to the in-hospital and long-term outcomes models except stent type [DES or BMS] was removed). Importantly, patients were matched on several variables associated with stent selection such as bleeding in the prior year, contraindication to prior antithrombotics, antiplatelet therapy, aspirin use, and known Coumadin administration at admission or in the catheterization laboratory. The propensity scores represent the estimated probabilities of receiving a DES (versus BMS), and the propensity score logistic regression models had c indexes of 0.738 for men and 0.747 for women (see the online-only Data Supplement). The Greedy 531 Digit Matching Algorithm was used to match each pair of device types on the basis of the propensity scores. After propensity matching, the distribution of estimated propensity scores for patients with DES closely matched that for patients with BMS as evidenced by the 5-number summaries (minimum, 25th percentile, 50th percentile, 75th percentile, maximum) describing the curves for patients receiving each type of device: men: DES, 10 To directly test the interaction between stent type and sex, the male and female propensity score-matched cohorts were combined. Cox models were created that included stent type (DES/BMS), sex (women/men), and sex/stent interaction for each end point. In all calculations, statistical significance was defined as PϽ0.05 with no correction for multiple comparisons. All analyses were performed at the Duke Clinical Research Institute with SAS statistical software (version 9.2; SAS Institute, Cary, NC).
Results
Population
Between January 1, 2004, and December 31, 2008, 675 460 patients Ն65 years of age underwent index stenting with either BMS or DES, and 67.6% were linked to Medicare data ( Figure 1 ). Although patients matched to Medicare are similar to the overall Medicare and CathPCI Registry populations, comparison of CathPCI Registry patients who did and did not match to Medicare fee-for-service records revealed unmatched patients to be slightly younger (age, 73.0 versus 74.0 years), more likely to be men (62% versus 58%), and less likely to be white (83% versus 89%), as previously reported. 21 Tables  1 and 2 ). Procedural success rates were slightly higher in women than in men (Table 3) .
Women experienced higher rates of all-cause in-hospital mortality than men (unadjusted event rate, 2.2% versus 1.6%; adjusted odd ratio [ Table 3 ).
Long-Term Outcomes by Sex
At 30 months of follow-up, women had a higher unadjusted incidence of death (16.3 versus 15.8 per 100 patients) compared with men. After adjustment, women were noted to have a lower risk of death (HR, 0.92; 95% CI, 0.90 -0.94; Table 4 ). The unadjusted rate of MI at 30 months was similar by sex (7.8 per 100 patients in women versus 7.6 per 100 patients in men; Pϭ0.87). The adjusted risk of long-term MI was similar between women and men (HR, 0.99; 95% CI, 0.95-1.03; Table 4 ). Similarly, no sex-associated differences in adjusted rates of bleeding (HR, 1.03; 95% CI, 0.98 -1.09) or repeat revascularization rates (HR, 0.99; 95% CI, 0.97-1.02; Table 4 ) were found. 
Long-Term Outcomes in Women and Men Undergoing DES Versus BMS Stenting
The unadjusted incidence of death at 30 months was lower in patients treated with DES versus BMS for both women (14.0% versus 23.0%) and men (13.6% versus 21.8%). The lower risk of death associated with DES use persisted after adjustment (women: HR, 0.78; 95% CI, 0.76 -0.81; men: HR, 0.77; 95% CI, 0.74 -0.79). A similar relative benefit associated with DES versus BMS was observed in both women and men (P for interactionϭ0.63; Table 5 and Figure 2 ).
Both sexes experienced similar benefit associated with DES versus BMS use for MI and repeat revascularization (women: HR, 0.93; 95% CI, 0.90 -0.97; men: HR, 0.91; 95% CI, 0.88 -0.94; P for interaction: MI, 0.14; repeat revascularization, 0.15; Table 5 and Figure 2 ). Among men and women, no BSA indicates body surface area; CHF, congestive heart failure; HTN, hypertension; CVA, cerebrovascular accident; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; MI, myocardial infarction; UA, unstable angina; NSTEMI, non-ST-segment-elevation myocardial infarction; SD, standardized difference; STEMI, ST-segment-elevation myocardial infarction; DES, drug-eluting stent; IABP, intra-aortic balloon pump; and LVEF, left ventricular ejection fraction.
*72.6% of population with EF assessment (308 972 patients).
differences were noted at 30 months for those treated with DES versus BMS or after risk adjustment (P for interaction by sex and stent typeϭ0.63).
Discussion
In this large contemporary cohort of older individuals undergoing coronary stenting, women experienced an increased risk of in-hospital death and complications compared with men. However, in long-term follow-up, women had a lower risk of death and a similar risk of MI, revascularization, and bleeding compared with men. Both men and women who were selected to receive DES experienced lower rates of death, MI, and revascularization compared with those who received BMS, and the long-term benefits of DES (versus BMS) were similar in women and men. To the best of our knowledge, our study is the largest to date to address sex-based stenting outcomes. BSA indicates body surface area; CHF, congestive heart failure; HTN, hypertension; CVA, cerebrovascular accident; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; MI, myocardial infarction; UA, unstable angina; NSTEMI, non-ST-segment-elevation myocardial infarction; STEMI, ST-segmentelevation myocardial infarction; DES, drug-eluting stent; IABP, intra-aortic balloon pump; and LVEF, left ventricular ejection fraction.
In our study, women undergoing stenting had increased risks of in-hospital death and complications. Although prior analyses are conflicting, the preponderance of evidence suggests that women are more likely to experience in-hospital mortality and complications. 4, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] Various studies have hypothesized that this increased risk is due to a greater burden of comorbidities, older age, smaller body size, and/or less aggressive pharmacological therapy. Yet, in our study, women remained at a significantly increased risk despite extensive adjustment for Ͼ50 clinical variables, including those mentioned by other authors such as clinical risk profile, age, body surface area, kidney disease, antiplatelet and anticoagulant therapy, and acuity of disease. Furthermore, these findings suggest that recent advances in care since earlier articles such as the establishment of sex-based guidelines for weight-based anticoagulation therapy, 34 the availability of smaller stent-based therapies, and smaller-vascularaccess devices either are underused or have not eliminated the sex-mortality gap. The reasons for this persistent difference in outcome are unknown but may be related to unmeasured confounders associated with prehospital factors in acute coronary syndromes (ie, delays in seeking or receiving care), differences in the percutaneous intervention itself, and/or the use and dosage of adjunctive therapies (such as anticoagulation). 34, 35 Although the absolute numbers of complications and death during the periprocedural period were low, sex still remains a significant risk factor for in-hospital death and complications. These findings emphasize the need for continued study in this area.
In contrast to in-hospital outcomes, long-term outcomes were clinically similar between men and women. Statistically, women had a lower risk of death and similar risks of longitudinal adverse outcomes of MI, revascularization, or bleeding. Although smaller observational studies (ie, 150 - 
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2000 women) with populations from the 1980s to late 1990s 3,5,26,27,31,36 -38 yielded mixed results on long-term outcomes, our findings significantly extend these prior reports by including a much larger cohort of stented patients, containing extensive risk adjustment, and reporting results from the contemporary DES era. Furthermore, our study included Ͼ42% women, which is significantly more than previous stent-based observational studies or trials. Although the reasons for the differences in relative short-and long-term outcomes between men and women are unclear, it is possible that once women are identified as having coronary artery disease (ie, after index stenting), they may receive increased aggressive secondary preventive care and attention to recurrent symptomatic coronary artery disease (as evidenced by equal rates of revascularization rates), thereby resulting in long-term clinical outcomes similar to those of men in the contemporary stenting era. 5, 36 In parallel with the finding of largely similar long-term outcomes in men and women, we found associations of reduced risk of events in women receiving DES versus BMS similar to those in men receiving DES versus BMS, and there was no interaction between sex and stent type for any outcome. Prior small pooled trial studies assessing DES use have yielded similar trends toward long-term outcomes by sex. 12, 13, 39, 40 The DES benefit in our study may reflect a bias toward a preferential use of BMS in higher-risk or sicker patients, which cannot be directly addressed in our data set. Furthermore, variables associated with stent selection such as upcoming surgery, compliance with antiplatelet therapy, and quantification of bleeding risk are not routinely collected in most registries. Nevertheless, it is significant that, if confounders are operating, their effects seem to apply to men and women equally.
Although the findings of reductions in death and MI with DES are at odds with most randomized clinical trials, 6 -11 these findings are congruent with most observational studies, 14, [41] [42] [43] and the magnitude of differences in stent-based mortality is similar to that reported by other registries. Specifically, a prior observational propensity-matched analysis comparing DES and BMS in Medicare beneficiaries found significant improvements in outcomes based on adjusted HR mortality (HR, 0.83; 95% CI, 0.81-0.86), acute MI (HR, 0.80; 95% CI, 0.78 -0.83), and revascularization (HR, 0.87; 95% CI, 0.85-0.90). 42 A few smaller (ie, Ͻ3000 women) sex-specific analyses comparing outcomes by stent type have suggested similar outcomes in women and men. 12, 13, 44 
Limitations
Our very large, nationally representative sample provides a unique opportunity to define both short-and long-term outcomes in men and women undergoing coronary stenting; however, our study has several limitations. First, our extensive adjustment for baseline differences strengthens the findings but cannot fully eliminate them. As a result, it is possible that unmeasured confounders and selection bias exist and may have contributed to the differences observed. Second, our study is observational and therefore is dependent on the data already collected, as well as the accuracy and completeness of the matched data set. Third, our findings of the potential benefit of DES over BMS for several outcomes should be interpreted with caution. Despite extensive adjustment, it is recognized that stent selection is biased toward a patient's clinical profile and risk, as well as socioeconomic factors (which may not be accounted for fully with propensity matching). Nevertheless, we believe that if unmeasured confounders are present, they most likely affect outcomes equally in men and women, therefore supporting the validity of our comparisons and findings. Stenting outcomes may also be dependent on specific provider procedural volume, which was not available in the NCDR database. Fourth, propensity matching reduced the study to 48.7% (208 052 men and women) of the NCDR-CMS cohort. Although we believe that this method yields results closer to randomization than other possible methods, we recognize that our data may not be reflective of the entire NCDR-CMS cohort or the general clinical population. Fifth, our study included only elderly patients. As a result, our findings are not applicable to patients Ͻ65 years of age. Finally, although our NCDR-CMS study population was robust, our linkage rate of 67.6% was incomplete. However, the remaining 33.4% of the NCDR population is reflective of populations known to be absent from the Medicare data set (ie, patients treated at government facilities such as the Veteran's Affairs and military hospitals, those with Medicare Advantage insurance coverage, or those who underwent outpatient procedures).
Conclusions
Our study afforded the unique opportunity to explore inhospital and long-term outcomes by sex and to compare the long-term safety and effectiveness of DES and BMS in women and men. In the contemporary PCI era, women remain at higher risk of in-hospital mortality and other complications. In contrast, long-term outcomes are similar or better in women and men. Use of DES is associated with a similar benefit in both men and women. Further studies should be directed at understanding causative factors for these findings. The funding organization had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.
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CLINICAL PERSPECTIVE
Coronary stenting has become a standard of care for the treatment of medically refractory coronary artery disease, with approximately one third of percutaneous coronary interventions (PCIs) performed in women in the United States. Although procedural success rates are similar by sex, it remains unclear whether disparate in-hospital and long-term outcomes exist between the sexes. In addition, the long-term safety and effectiveness of drug-eluting stents relative to bare metal stents in women are poorly understood. Women have been underrepresented in prior clinical trials evaluating intracoronary stent technologies, and smaller historical observational studies have produced conflicting results. Data from Ͼ400 000 older individuals (Ն65 years of age) from the National Cardiovascular Data Registry CathPCI Registry were linked to Medicare inpatient claims to study sex-specific in-hospital and long-term outcomes after an index stent procedure. Additionally, the long-term safety and effectiveness of drug-eluting stents versus bare metal stents were compared in women and men. In the contemporary PCI era, our study shows that elderly women undergoing index PCI remain at higher risk of in-hospital mortality and other complications compared with men. In contrast, long-term outcomes are similar or better in women than in men. The use of drug-eluting stents is associated with a similar benefit in both men and women. Further studies are needed to understand the causative factors for these findings. 
